Atsena Therapeutics and Nippon Shinyaku Enter Exclusive License Agreement for ATSN-101
Atsena Therapeutics Inc., a UF Startup, has entered into an exclusive license agreement with Nippon Shinyaku Co., Ltd. for the commercialization of ATSN-101 in the United States, and for its development and commercialization in Japan.
